April 27, 2023 View Now | Clinical Outcome Assessments: Does one size fit all? Join C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform and its Rare Disease Clinical Outcome Assessment
The Rare Disease Clinical Outcome Assessment Consortium: Aiming to Fulfill Unmet Drug Development Endpoint Measurement Needs Appropriate endpoint selection for rare disease trials is challenging. The Rare Disease Clinical Outcome Assessment (COA)....
March 16, 2023 Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature According to the latest guidelines by the Infectious Disease Society of America (IDSA), there is no defined standard of care for..
March 15, 2023 Evaluation of Novel Urinary Biomarkers in Beagle Dogs With Amphotericin B-Induced Kidney Injury
March 14, 2023 C-Path Welcomes BioCentury Inc. Co-Founder Bernstein to Board of Directors Dr. Bernstein will help steer the strategic vision of C-Path as the organization’s newest board member TUCSON, Ariz., March 14,
C-Path Welcomes TransPerfect Life Sciences C-Path is proud to welcome TransPerfect Life Sciences as the newest member of its Electronic Clinical Outcome Asse
March 8, 2023 Establishing a Basis for Secondary Use Standards for Clinical Trials Study seeks to understand how different forms of data meet the needs of researchers.
March 15, 2023 View Now | CP-RND: An Introduction to the Patient Community Hosted by the C-Path team, you can view this recorded webinar to learn more about the Critical Path for Rare Neurodegenerative Dis
C-Path Stands with Bruce Willis, Neurodegenerative Disease Community After FTD Diagnosis C-Path and its members stand with Bruce Willis and his family as they bravely revealed the difficult news of his Frontotemporal De
February 16, 2023 Leveraging the SCCM Discovery Virus COVID-19 Registry to Evaluate Drug Repurposing Research Dataset The CURE Repurposing Collaboratory (CDRC) partnered with the SCCM Discovery Virus COVID-19 Registry (Virus) to develop and build..